ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a leading player in the biopharmaceutical industry, is headquartered in Shanghai, China. Founded in 2015, the company has rapidly established itself as a pioneer in the development of innovative immuno-oncology therapies, focusing on harnessing the body’s immune system to combat cancer. With a robust portfolio of unique products and services, ImmuneOnco is dedicated to advancing cancer treatment through cutting-edge research and development. The company’s commitment to excellence has positioned it as a key contributor in the global biopharmaceutical landscape, particularly in the Asia-Pacific region. Notable achievements include significant partnerships and advancements in clinical trials, underscoring its role in transforming cancer care.
DitchCarbon Score
How does ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s score of 15 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s reported carbon emissions
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., headquartered in China, currently does not have available carbon emissions data or specific reduction targets. As a biopharmaceutical company, it is essential for them to engage in climate commitments and sustainability initiatives, particularly in an industry increasingly focused on reducing environmental impact. While no specific emissions figures or reduction initiatives have been disclosed, the company may still be exploring strategies to align with industry standards for climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
